Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1038/ejcn.2012.60. Epub 2012 Jun 6.
Affiliations
- PMID: 22669332
- DOI: 10.1038/ejcn.2012.60
Randomized Controlled Trial
Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial
C Signori et al. Eur J Clin Nutr. 2012 Aug.
Abstract
Background/objectives: The antiestrogen, Raloxifene (Ral) is an effective breast cancer chemopreventive agent. Omega-3 fatty acids (n-3FA) may inhibit mammary carcinogenesis. On the basis of their mechanisms of action, we test the hypothesis that a combination of n-3FA and Ral may be superior in reducing select biomarkers of breast cancer risk in women.
Subjects/methods: Postmenopausal women at increased risk for breast cancer (breast density ≥ 25%) were randomized to: (1) no intervention; (2) Ral 60 mg; (3) Ral 30 mg; (4) n-3FA (Lovaza) 4 g and (5) Lovaza 4 g+Ral 30 mg for 2 years. Reduction in breast density is the primary end point of the study. We report preliminary data on feasibility, compliance and changes in secondary end points related to IGF-I signaling, estrogen metabolism, oxidative stress and inflammation in the first group of 46 women who completed 1 year of the study.
Results: All interventions were well tolerated with excellent compliance (96 ± 1% overall) by pill count and also supported by the expected rise in both serum n-3FA and n-3FA/Omega-6 fatty acids (n-6FA) ratio in women randomized to groups 4 and 5 (P<0.05). Lovaza decreased serum triglycerides and increased high-density lipoprotein (HDL) cholesterol compared with control (P<0.05 for both). Ral reduced serum IGF-1 in a dose-dependent manner (P<0.05) while Lovaza did not. Lovaza had no effect on IGF-1 or IGFBP-3. None of the other biomarkers were affected by our treatment.
Conclusion: The combination of Lovaza and Ral is a feasible strategy that may be recommended in future breast cancer chemoprevention trials.
Similar articles
- Influence of Obesity on Breast Density Reduction by Omega-3 Fatty Acids: Evidence from a Randomized Clinical Trial.
Sandhu N, Schetter SE, Liao J, Hartman TJ, Richie JP, McGinley J, Thompson HJ, Prokopczyk B, DuBrock C, Signori C, Hamilton C, Calcagnotto A, Trushin N, Aliaga C, Demers LM, El-Bayoumy K, Manni A. Sandhu N, et al. Cancer Prev Res (Phila). 2016 Apr;9(4):275-82. doi: 10.1158/1940-6207.CAPR-15-0235. Epub 2015 Dec 29. Cancer Prev Res (Phila). 2016. PMID: 26714774 Clinical Trial. - Stearoyl-CoA desaturase-1, a novel target of omega-3 fatty acids for reducing breast cancer risk in obese postmenopausal women.
Manni A, Richie JP, Schetter SE, Calcagnotto A, Trushin N, Aliaga C, El-Bayoumy K. Manni A, et al. Eur J Clin Nutr. 2017 Jun;71(6):762-765. doi: 10.1038/ejcn.2016.273. Epub 2017 Feb 1. Eur J Clin Nutr. 2017. PMID: 28145413 Clinical Trial. - Omega-3 Fatty Acids Responsive Proteins and Reduction in Breast Density in Obese Postmenopausal Women.
Sun YW, Xu H, Benitez G, Chen KM, Stanley A, Stanley B, Zhu J, Thompson H, Manni A, El-Bayoumy K. Sun YW, et al. J Proteome Res. 2019 Sep 6;18(9):3461-3469. doi: 10.1021/acs.jproteome.9b00356. Epub 2019 Aug 14. J Proteome Res. 2019. PMID: 31369706 - Combination of Antiestrogens and Omega-3 Fatty Acids for Breast Cancer Prevention.
Manni A, El-Bayoumy K, Skibinski CG, Thompson HJ, Santucci-Pereira J, Bidinotto LT, Russo J. Manni A, et al. Biomed Res Int. 2015;2015:638645. doi: 10.1155/2015/638645. Epub 2015 Aug 3. Biomed Res Int. 2015. PMID: 26339626 Free PMC article. Review. - Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH, Komm BS. Pickar JH, et al. Post Reprod Health. 2015 Sep;21(3):112-21. doi: 10.1177/2053369115599090. Epub 2015 Aug 19. Post Reprod Health. 2015. PMID: 26289836 Review.
Cited by
- Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo.
Sun D, Jones NR, Manni A, Lazarus P. Sun D, et al. Cancer Prev Res (Phila). 2013 Jul;6(7):719-30. doi: 10.1158/1940-6207.CAPR-12-0448. Epub 2013 May 16. Cancer Prev Res (Phila). 2013. PMID: 23682072 Free PMC article. - Emerging targets in lipid-based therapy.
Tucker SC, Honn KV. Tucker SC, et al. Biochem Pharmacol. 2013 Mar 1;85(5):673-688. doi: 10.1016/j.bcp.2012.11.028. Epub 2012 Dec 20. Biochem Pharmacol. 2013. PMID: 23261527 Free PMC article. Review. - Building a Foundation for Precision Onco-Nutrition: Docosahexaenoic Acid and Breast Cancer.
Thompson HJ, Neil ES, McGinley JN, Fitzgerald VK, El Bayoumy K, Manni A. Thompson HJ, et al. Cancers (Basel). 2021 Dec 29;14(1):157. doi: 10.3390/cancers14010157. Cancers (Basel). 2021. PMID: 35008321 Free PMC article. - Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome.
Singhal S, Riggs ED, Ruth KJ, Chavez-Salas JP, Chertock Y, Daly MB, Hall MJ. Singhal S, et al. JCO Precis Oncol. 2024 Oct;8:e2400562. doi: 10.1200/PO-24-00562. Epub 2024 Nov 15. JCO Precis Oncol. 2024. PMID: 39546469 - Synergic Role of Dietary Bioactive Compounds in Breast Cancer Chemoprevention and Combination Therapies.
Mecca M, Sichetti M, Giuseffi M, Giglio E, Sabato C, Sanseverino F, Marino G. Mecca M, et al. Nutrients. 2024 Jun 14;16(12):1883. doi: 10.3390/nu16121883. Nutrients. 2024. PMID: 38931238 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous